Integra LifeSciences Holdings Corporation — Q1 2015 Form 10-Q
Business context and reporting period
Unaudited results cover the three months ended March 31, 2015, compared with the same period in 2014. Integra is a medical technology company serving orthopedic extremity, neurosurgery, spine, reconstructive and general surgery markets. Beginning in 2015, the Company reported three global segments: Specialty Surgical Solutions, Orthopedics and Tissue Technologies, and Spine.
Key financial metrics
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Revenue | $233.7 million | $215.1 million | Up 8.7% |
| Gross profit | $146.9 million | $132.7 million | Up 10.8% |
| Gross margin | 62.9% | 61.7% | Up 120 bps |
| Operating income | $16.8 million | $8.7 million | Up 92.1% |
| Net income | $8.4 million | $2.2 million | Up $6.2 million |
| Diluted EPS | $0.25 | $0.07 | Up $0.18 |
| Operating cash flow | $31.6 million | $11.3 million | Up $20.4 million |
Operating margin was approximately 7.2%, compared with 4.1% in the prior-year quarter. Net margin was approximately 3.6%, compared with 1.0%. The effective tax rate declined to 33.5% from 44.5%, primarily because Q1 2014 included $0.8 million of foreign and state tax audit settlement expense.
At March 31, 2015, cash and equivalents were $79.9 million, compared with $72.0 million at December 31, 2014. Working capital was $395.1 million. Carrying debt consisted of $401.9 million under the Senior Credit Facility and $215.2 million of convertible securities. Approximately $498.1 million remained available under the credit facility, and the Company was in compliance with its covenants.
Segment and operating developments
- Specialty Surgical Solutions revenue was $140.1 million, up 10%, supported by MicroFrance, dural repair, neuro critical care and instruments; tissue ablation declined.
- Orthopedics and Tissue Technologies revenue was $61.4 million, up 12%, supported by Metasurg, regenerative technologies and upper-extremity products.
- Spine revenue was $32.2 million, down 3%, reflecting pricing pressure, delayed product launches and slower distributor additions.
- U.S. revenue was $181.0 million, or 77% of total revenue. Foreign exchange reduced sales by approximately $5.8 million year over year.
Material changes versus the prior comparable period
- Q1 2015 included revenue of approximately $5.8 million from MicroFrance and $1.6 million from Metasurg. Q1 2014 included a full quarter of Confluent Surgical revenue of approximately $14.1 million; Q1 2015 included approximately $17.7 million.
- Operating performance benefited from increased sales of higher-margin products and improved regenerative-product manufacturing utilization.
- Operating expenses increased 5% to $130.2 million, while operating expenses as a percentage of revenue declined to 55.7% from 57.6%.
- The Company incurred $4.8 million of Spine separation costs in Q1 2015 and expects additional separation costs during 2015.
- Goodwill was reallocated following the segment realignment. The Spine reporting unit recorded a $0.4 million goodwill impairment charge.
- Comprehensive loss was $15.7 million versus comprehensive income of $3.2 million, primarily due to a $24.4 million foreign-currency translation loss.
- Net cash used in financing was $13.8 million, including a $15.0 million repayment of revolving debt. Q1 2014 included $235.0 million of acquisition-related borrowings.
Guidance, outlook, risks and unusual items
- Management expects 2015 gross margin of 62.0% to 62.5%, research and development expense of 5.5% to 6.0% of revenue, selling, general and administrative expense of 47.5% to 48.0% of revenue, and an effective tax rate of approximately 29% to 30%.
- Planned 2015 capital expenditures are $40 million to $45 million. Management also expects to provide $40 million to $50 million of cash to the Spine business and spend approximately $20 million on separation-related professional fees and infrastructure.
- The planned tax-free Spine spin-off was expected in the second half of 2015, subject to regulatory approvals, tax assurances, an effective Form 10 registration statement and Board approval. Completion and timing were not assured.
- The Company filed an FDA Premarket Approval Supplement for its diabetic foot ulcer product and anticipated potential commercialization in mid-2016, assuming FDA approval and timely publication of clinical data.
- Special charges totaled $16.8 million, including ERP implementation, structural optimization, severance, acquisition-related charges, impairment, convertible-debt non-cash interest and Spine separation costs.
- Risks include foreign-currency volatility, dependence on regulatory approvals and reimbursement, product liability and litigation, acquisition integration, goodwill and intangible-asset impairment, debt refinancing, and execution of the Spine separation. The Company also has contingent consideration with a fair value of $22.1 million and uncertain tax benefits of $1.1 million, excluded from the contractual-obligations table.
- The FDA warning letter relating to the Añasco facility was closed effective January 14, 2015. The Andover, UK facility was closed and removed from the FDA-registered facility list on December 31, 2014.
Important facts for investors to verify
- Progress, final costs, financing and tax treatment of the planned Spine spin-off.
- Whether reported revenue growth persists after accounting for MicroFrance, Metasurg and Confluent Surgical acquisition contributions.
- Foreign-exchange effects, particularly the euro, and their impact on revenue and margins.
- Availability and refinancing plans for the $230.0 million convertible notes due in 2016 and the Company’s other borrowings.
- FDA approval and reimbursement prospects for the diabetic foot ulcer indication.
- Future goodwill or intangible-asset impairment risk, especially for the Spine business.